Experience in daily practice with ipilimumab for thetreatment of patients with metastatic melanoma: Anearly increase in lymphocyte and eosinophil countsis associated with improved survival

J. Delyon; C. Mateus; D. Lefeuvre; E. Lanoy; L. Zitvogel; N. Chaput; S. Roy; A. M.M. Eggermont; E. Routier; C. Robert

doi:10.1093/annonc/mdt027

Experience in daily practice with ipilimumab for thetreatment of patients with metastatic melanoma: Anearly increase in lymphocyte and eosinophil countsis associated with improved survival

J. Delyon, C. Mateus, D. Lefeuvre, E. Lanoy, L. Zitvogel, N. Chaput, S. Roy, A. M.M. Eggermont, E. Routier, C. Robert

Research output: Contribution to journal › Article › peer-review

275 Citations (Scopus)

Abstract

Background: Ipilimumab is a recently approved immunotherapy that has demonstrated an improvement in the overallsurvival (OS) of patients with metastatic melanoma. We report a single-institution experience in patients treated in acompassionate-use program.Patients and methods: In this prospective study, patients were treated between June 2010 and September 2011.Inclusion criteria were a diagnosis of unresectable stage III or IV melanoma, at least one previous line of chemotherapy,and survival 12 weeks after the first perfusion. Four courses of ipilimumab were administered at a dose of 3 mg/kgevery 3 weeks.

Original language	English
Pages (from-to)	1697-1703
Number of pages	7
Journal	Annals of Oncology
Volume	24
Issue number	6
DOIs	https://doi.org/10.1093/annonc/mdt027
Publication status	Published - 1 Jan 2013

Access to Document

10.1093/annonc/mdt027

Cite this

Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A. M. M., Routier, E., & Robert, C. (2013). Experience in daily practice with ipilimumab for thetreatment of patients with metastatic melanoma: Anearly increase in lymphocyte and eosinophil countsis associated with improved survival. Annals of Oncology, 24(6), 1697-1703. https://doi.org/10.1093/annonc/mdt027

@article{6f8f5f62368b4149b0885d21901895c3,

title = "Experience in daily practice with ipilimumab for thetreatment of patients with metastatic melanoma: Anearly increase in lymphocyte and eosinophil countsis associated with improved survival",

abstract = "Background: Ipilimumab is a recently approved immunotherapy that has demonstrated an improvement in the overallsurvival (OS) of patients with metastatic melanoma. We report a single-institution experience in patients treated in acompassionate-use program.Patients and methods: In this prospective study, patients were treated between June 2010 and September 2011.Inclusion criteria were a diagnosis of unresectable stage III or IV melanoma, at least one previous line of chemotherapy,and survival 12 weeks after the first perfusion. Four courses of ipilimumab were administered at a dose of 3 mg/kgevery 3 weeks.",

author = "J. Delyon and C. Mateus and D. Lefeuvre and E. Lanoy and L. Zitvogel and N. Chaput and S. Roy and Eggermont, {A. M.M.} and E. Routier and C. Robert",

year = "2013",

month = jan,

day = "1",

doi = "10.1093/annonc/mdt027",

language = "English",

volume = "24",

pages = "1697--1703",

journal = "Annals of Oncology",

issn = "0923-7534",

number = "6",

}

Delyon, J, Mateus, C, Lefeuvre, D, Lanoy, E, Zitvogel, L, Chaput, N, Roy, S, Eggermont, AMM, Routier, E & Robert, C 2013, 'Experience in daily practice with ipilimumab for thetreatment of patients with metastatic melanoma: Anearly increase in lymphocyte and eosinophil countsis associated with improved survival', Annals of Oncology, vol. 24, no. 6, pp. 1697-1703. https://doi.org/10.1093/annonc/mdt027

TY - JOUR

T1 - Experience in daily practice with ipilimumab for thetreatment of patients with metastatic melanoma

T2 - Anearly increase in lymphocyte and eosinophil countsis associated with improved survival

AU - Delyon, J.

AU - Mateus, C.

AU - Lefeuvre, D.

AU - Lanoy, E.

AU - Zitvogel, L.

AU - Chaput, N.

AU - Roy, S.

AU - Eggermont, A. M.M.

AU - Routier, E.

AU - Robert, C.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Background: Ipilimumab is a recently approved immunotherapy that has demonstrated an improvement in the overallsurvival (OS) of patients with metastatic melanoma. We report a single-institution experience in patients treated in acompassionate-use program.Patients and methods: In this prospective study, patients were treated between June 2010 and September 2011.Inclusion criteria were a diagnosis of unresectable stage III or IV melanoma, at least one previous line of chemotherapy,and survival 12 weeks after the first perfusion. Four courses of ipilimumab were administered at a dose of 3 mg/kgevery 3 weeks.

AB - Background: Ipilimumab is a recently approved immunotherapy that has demonstrated an improvement in the overallsurvival (OS) of patients with metastatic melanoma. We report a single-institution experience in patients treated in acompassionate-use program.Patients and methods: In this prospective study, patients were treated between June 2010 and September 2011.Inclusion criteria were a diagnosis of unresectable stage III or IV melanoma, at least one previous line of chemotherapy,and survival 12 weeks after the first perfusion. Four courses of ipilimumab were administered at a dose of 3 mg/kgevery 3 weeks.

UR - http://www.scopus.com/inward/record.url?scp=84878432797&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdt027

DO - 10.1093/annonc/mdt027

M3 - Article

C2 - 23439861

AN - SCOPUS:84878432797

SN - 0923-7534

VL - 24

SP - 1697

EP - 1703

JO - Annals of Oncology

JF - Annals of Oncology

IS - 6

ER -

Experience in daily practice with ipilimumab for thetreatment of patients with metastatic melanoma: Anearly increase in lymphocyte and eosinophil countsis associated with improved survival

Abstract

Access to Document

Other files and links

Cite this